IP Library › Granted Patent US 12,583,922
Granted Patent B2
US 12,583,922 · App. 17/701,570 · Granted Mar 24, 2026

Bispecific antibodies targeting CD47 and PD-L1 and methods of use thereof

Inventors: Xavier Chauchet (Geneva, CH); Krzysztof Masternak (Mollens, CH); Limin Shang (Bellevue, CH); Elise Penarrieta (Crans-Montana, CH); Walter Ferlin (Collonges-Sous-Salève, CH)
Assignee: Novimmune SA
C07K16/2803C07K16/2896C07K16/461C07K16/468A61K2039/505C07K2317/31C07K2317/565C07K2317/622C07K2317/76C07K2317/92
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,583,922
App. No.
17/701,570
Granted
Mar 24, 2026
Kind
B2
Abstract

This disclosure provides bispecific antibodies that specifically bind to CD47 and Programmed Death-Ligand 1 (PD-L1). The disclosure further relates to methods of making the bispecific antibodies and nucleic acids encoding the antibodies. The disclosure further relates to therapeutic methods for use of the bispecific antibodies in the treatment of a condition associated with malignant cells expressing CD47 and/or PD-L1.

Claims (242)

1 . A bispecific antibody comprising:

i) a heavy chain comprising

a heavy chain complementarity determining region 1 (CDRH1) comprising an amino acid sequence of SEQ ID NO: 1;

a heavy chain complementarity determining region 2 (CDRH2) comprising an amino acid sequence of SEQ ID NO: 2; and

a heavy chain complementarity determining region 3 (CDRH3) comprising an amino acid sequence of SEQ ID NO: 3;

ii) a first light chain comprising

a light chain complementarity determining region 1 (CDRL1) comprising an amino acid sequence of SEQ ID NO: 89;

a light chain complementarity determining region 2 (CDRL2) comprising an amino acid sequence of Ala-Ala-Ser; and

a light chain complementarity determining region 3 (CDRL3) comprising an amino acid sequence of SEQ ID NO: 96; and

iii) a second light chain comprising:

a) a CDRL1 comprising an amino acid sequence of SEQ ID NO: 8;

a CDRL2 comprising an amino acid sequence of Ala-Thr-Asn; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 20; or

b) a CDRL1 comprising an amino acid sequence of SEQ ID NO: 8;

a CDRL2 comprising an amino acid sequence of Ala-Thr-Asn; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 21; or

c) a CDRL1 comprising an amino acid sequence of SEQ ID NO: 8;

a CDRL2 comprising an amino acid sequence of Ala-Thr-Asn; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 22; or

d) a CDRL1 comprising an amino acid sequence of SEQ ID NO: 9;

a CDRL2 comprising an amino acid sequence of Phe-Gly-Ser; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 23; or

e) a CDRL1 comprising an amino acid sequence of SEQ ID NO: 9;

a CDRL2 comprising an amino acid sequence of Phe-Gly-Ser; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 24; or

f) a CDRL1 comprising an amino acid sequence of SEQ ID NO: 9;

a CDRL2 comprising an amino acid sequence of Phe-Gly-Ser; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 25; or

g) a CDRL1 comprising an amino acid sequence of SEQ ID NO: 10;

a CDRL2 comprising an amino acid sequence of His-Asp-Asn; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 97; or

h) a CDRL1 comprising an amino acid sequence of SEQ ID NO: 10;

a CDRL2 comprising an amino acid sequence of His-Asp-Asn; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 98; or

i) a CDRL1 comprising an amino acid sequence of SEQ ID NO: 11;

a CDRL2 comprising an amino acid sequence of His-Asp-Thr; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 97; or

j) a CDRL1 comprising an amino acid sequence of SEQ ID NO: 12;

a CDRL2 comprising an amino acid sequence of Phe-Ala-Ser; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 26; or

k) a CDRL1 comprising an amino acid sequence of SEQ ID NO: 13;

a CDRL2 comprising an amino acid sequence of Phe-Ala-Ser; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 26; or

l) a CDRL1 comprising an amino acid sequence of SEQ ID NO: 14;

a CDRL2 comprising an amino acid sequence of Phe-Ala-Ser; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 27; or

m) a CDRL1 comprising an amino acid sequence of SEQ ID NO: 14;

a CDRL2 comprising an amino acid sequence of Phe-Ala-Ser; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 28; or

n) a CDRL1 comprising the amino acid sequence of SEQ ID NO: 101;

a CDRL2 comprising the amino acid sequence of His-Asp-Thr; and

a CDRL3 comprising the amino acid sequence of SEQ ID NO: 97; or

o) a CDRL1 comprising the amino acid sequence of SEQ ID NO: 102;

a CDRL2 comprising the amino acid sequence of His-Asp-Thr; and

a CDRL3 comprising the amino acid sequence of SEQ ID NO: 97; or

p) a CDRL1 comprising the amino acid sequence of SEQ ID NO: 103;

a CDRL2 comprising the amino acid sequence of His-Asp-Thr; and

a CDRL3 comprising the amino acid sequence of SEQ ID NO: 97; and

wherein the bispecific antibody comprises a first antigen binding region comprising i) and ii) that specifically binds to CD47 and a second antigen binding region comprising i) and iii) that specifically binds to Programmed Death-ligand 1 (PD-L1).

2 . The isolated bispecific antibody of claim 1 , wherein at least a portion of the first light chain is of the kappa type and at least a portion of the second light chain is of the lambda type.

3 . The isolated bispecific antibody of claim 2 , wherein the first light chain comprises at least a Kappa constant region.

4 . The isolated bispecific antibody of claim 3 , wherein the first light chain further comprises a Kappa variable region.

5 . The isolated bispecific antibody of claim 3 , wherein the first light chain further comprises a Lambda variable region.

6 . The isolated bispecific antibody of claim 2 , wherein the second light chain comprises at least a Lambda constant region.

7 . The isolated bispecific antibody of claim 6 , wherein the second light chain further comprises a Lambda variable region.

8 . The isolated bispecific antibody of claim 5 , wherein the second light chain further comprises a Kappa variable region.

9 . The isolated bispecific antibody of claim 2 , wherein the first light chain comprises a Kappa constant region and a Kappa variable region, and wherein the second light chain comprises a Lambda constant region and a Lambda variable region.

10 . The bispecific antibody of claim 1 , wherein the bispecific antibody is human antibody.

11 . The bispecific antibody of claim 1 , wherein the bispecific antibody is an IgG1 antibody.

12 . A composition comprising the bispecific antibody of claim 1 and a pharmaceutically acceptable carrier.

13 . A method of treating a PD-L1+ or CD47+ solid tumor, killing a PD-L1+ or CD47+ tumor cell, or reducing the proliferation of a PD-L1+ or CD47+ tumor cell, comprising contacting the cell with a bispecific antibody comprising:

(i) a first antigen binding region comprising a heavy chain and a light chain, wherein the first antigen binding region binds CD47 and comprises:

(a) a CDRH1 comprising an amino acid sequence of SEQ ID NO: 1;

a CDRH2 comprising an amino acid sequence of SEQ ID NO: 2;

a CDRH3 comprising an amino acid sequence of SEQ ID NO: 3;

a CDRL1 comprising an amino acid sequence of SEQ ID NO: 89;

a CDRL2 comprising an amino acid sequence of Ala-Ala-Ser; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 96; and

(ii) a second antigen binding region comprising a heavy chain and a light chain, wherein the second antigen binding region binds PD-L1 and comprises:

(a) a CDRH1 comprising an amino acid sequence of SEQ ID NO: 1;

a CDRH2 comprising an amino acid sequence of SEQ ID NO: 2;

a CDRH3 comprising an amino acid sequence of SEQ ID NO: 3;

a CDRL1 comprising an amino acid sequence of SEQ ID NO: 103;

a CDRL2 comprising an amino acid sequence of His-Asp-Thr; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 97;

(b) a CDRH1 comprising an amino acid sequence of SEQ ID NO: 1;

a CDRH2 comprising an amino acid sequence of SEQ ID NO: 2;

a CDRH3 comprising an amino acid sequence of SEQ ID NO: 3;

a CDRL1 comprising an amino acid sequence of SEQ ID NO: 14;

a CDRL2 comprising an amino acid sequence of SEQ ID NO: 19; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 28;

(c) a CDRH1 comprising an amino acid sequence of SEQ ID NO: 1;

a CDRH2 comprising an amino acid sequence of SEQ ID NO: 2;

a CDRH3 comprising an amino acid sequence of SEQ ID NO: 3;

a CDRL1 comprising an amino acid sequence of SEQ ID NO: 102;

a CDRL2 comprising an amino acid sequence of His-Asp-Thr; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 97;

(d) a CDRH1 comprising an amino acid sequence of SEQ ID NO: 1;

a CDRH2 comprising an amino acid sequence of SEQ ID NO: 2;

a CDRH3 comprising an amino acid sequence of SEQ ID NO: 3;

a CDRL1 comprising an amino acid sequence of SEQ ID NO: 11;

a CDRL2 comprising an amino acid sequence of His-Asp-Thr; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 97;

(e) a CDRH1 comprising an amino acid sequence of SEQ ID NO: 1;

a CDRH2 comprising an amino acid sequence of SEQ ID NO: 2;

a CDRH3 comprising an amino acid sequence of SEQ ID NO: 3;

a CDRL1 comprising an amino acid sequence of SEQ ID NO: 9;

a CDRL2 comprising an amino acid sequence of Phe-Gly-Ser; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 24; or

(f) a CDRH1 comprising an amino acid sequence of SEQ ID NO: 1;

a CDRH2 comprising an amino acid sequence of SEQ ID NO: 2;

a CDRH3 comprising an amino acid sequence of SEQ ID NO: 3;

a CDRL1 comprising an amino acid sequence of SEQ ID NO: 12;

a CDRL2 comprising an amino acid sequence of Phe-Ala-Ser; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 26.

14 . The method of claim 13 , wherein the PD-L1+ or CD47+ solid tumor is or is derived from breast cancer, ovarian cancer, head and neck cancer, bladder cancer, melanoma, mesothelioma, colorectal cancer, cholangiocarcinoma, pancreatic cancer, lung cancer, leiomyoma, leiomyosarcoma, kidney cancer, glioma, glioblastoma, endometrial cancer, esophageal cancer, biliary gastric cancer, prostate cancer, or combinations thereof.

15 . An antibody comprising:

i) a heavy chain comprising:

a CDRH1 comprising an amino acid sequence of SEQ ID NO: 1;

a CDRH2 comprising an amino acid sequence of SEQ ID NO: 2; and

a CDRH3 comprising an amino acid sequence of SEQ ID NO: 3; and

ii) light chain comprising:

a) a CDRL1 comprising an amino acid sequence of SEQ ID NO: 8;

a CDRL2 comprising an amino acid sequence of Ala-Thr-Asn; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 20; or

b) a CDRL1 comprising an amino acid sequence of SEQ ID NO: 8;

a CDRL2 comprising an amino acid sequence of Ala-Thr-Asn; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 21; or

c) a CDRL1 comprising an amino acid sequence of SEQ ID NO: 8;

a CDRL2 comprising an amino acid sequence of Ala-Thr-Asn; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 22; or

d) a CDRL1 comprising an amino acid sequence of SEQ ID NO: 9;

a CDRL2 comprising an amino acid sequence of Phe-Gly-Ser; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 23; or

e) a CDRL1 comprising an amino acid sequence of SEQ ID NO: 9;

a CDRL2 comprising an amino acid sequence of Phe-Gly-Ser; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 24; or

f) a CDRL1 comprising an amino acid sequence of SEQ ID NO: 9;

a CDRL2 comprising an amino acid sequence of Phe-Gly-Ser; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 25; or

g) a CDRL1 comprising an amino acid sequence of SEQ ID NO: 10;

a CDRL2 comprising an amino acid sequence of His-Asp-Asn; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 97; or

h) a CDRL1 comprising an amino acid sequence of SEQ ID NO: 10;

a CDRL2 comprising an amino acid sequence of His-Asp-Asn; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 98; or

i) a CDRL1 comprising an amino acid sequence of SEQ ID NO: 11;

a CDRL2 comprising an amino acid sequence of His-Asp-Thr; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 97; or

j) a CDRL1 comprising an amino acid sequence of SEQ ID NO: 12;

a CDRL2 comprising an amino acid sequence of Phe-Ala-Ser; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 26; or

k) a CDRL1 comprising an amino acid sequence of SEQ ID NO: 13;

a CDRL2 comprising an amino acid sequence of Phe-Ala-Ser; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 26; or

l) a CDRL1 comprising an amino acid sequence of SEQ ID NO: 14;

a CDRL2 comprising an amino acid sequence of Phe-Ala-Ser; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 27; or

m) a CDRL1 comprising an amino acid sequence of SEQ ID NO: 14;

a CDRL2 comprising an amino acid sequence of Phe-Ala-Ser; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 28; or

n) a CDRL1 comprising the amino acid sequence of SEQ ID NO: 101;

a CDRL2 comprising the amino acid sequence of His-Asp-Thr; and

a CDRL3 comprising the amino acid sequence of SEQ ID NO: 97; or

o) a CDRL1 comprising the amino acid sequence of SEQ ID NO: 102;

a CDRL2 comprising the amino acid sequence of His-Asp-Thr; and

a CDRL3 comprising the amino acid sequence of SEQ ID NO: 97; or

p) a CDRL1 comprising the amino acid sequence of SEQ ID NO: 103;

a CDRL2 comprising the amino acid sequence of His-Asp-Thr; and

a CDRL3 comprising the amino acid sequence of SEQ ID NO: 97; and

wherein the antibody specifically binds to Programmed Death-ligand 1 (PD-L1).

16 . The antibody of claim 15 , wherein the antibody is human antibody.

17 . The antibody of claim 15 , wherein the antibody is an IgG1 antibody.

18 . The antibody of claim 15 , wherein the antibody is a F(ab) fragment, a F(ab′)2 fragment, and Fv fragment or a single chain Fv fragment.

19 . The antibody of claim 15 , wherein the antibody is monospecific.

20 . The antibody of claim 15 , wherein the antibody is monovalent.

21 . A composition comprising the antibody of claim 15 and a pharmaceutically acceptable carrier.

22 . A method of treating a PD-L1+ solid tumor, killing a PD-L1+ tumor cell, or reducing the proliferation of a PD-L1+ tumor cell, comprising contacting the cell with an antibody comprising:

an antigen binding region comprising a heavy chain and a light chain, wherein the antigen binding region binds PD-L1 and comprises:

(a) a CDRH1 comprising an amino acid sequence of SEQ ID NO: 1;

a CDRH2 comprising an amino acid sequence of SEQ ID NO: 2;

a CDRH3 comprising an amino acid sequence of SEQ ID NO: 3;

a CDRL1 comprising an amino acid sequence of SEQ ID NO: 103;

a CDRL2 comprising an amino acid sequence of SEQ ID NO: 18; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 97;

(b) a CDRH1 comprising an amino acid sequence of SEQ ID NO: 1;

a CDRH2 comprising an amino acid sequence of SEQ ID NO: 2;

a CDRH3 comprising an amino acid sequence of SEQ ID NO: 3;

a CDRL1 comprising an amino acid sequence of SEQ ID NO: 102;

a CDRL2 comprising an amino acid sequence of SEQ ID NO: 18; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 97;

c) a CDRH1 comprising an amino acid sequence of SEQ ID NO: 1;

a CDRH2 comprising an amino acid sequence of SEQ ID NO: 2;

a CDRH3 comprising an amino acid sequence of SEQ ID NO: 3;

a CDRL1 comprising an amino acid sequence of SEQ ID NO: 11;

a CDRL2 comprising an amino acid sequence of SEQ ID NO: 18; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 97;

(d) a CDRH1 comprising an amino acid sequence of SEQ ID NO: 1;

a CDRH2 comprising an amino acid sequence of SEQ ID NO: 2;

a CDRH3 comprising an amino acid sequence of SEQ ID NO: 3;

a CDRL1 comprising an amino acid sequence of SEQ ID NO: 14;

a CDRL2 comprising an amino acid sequence of SEQ ID NO: 19; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 28;

(e) a CDRH1 comprising an amino acid sequence of SEQ ID NO: 1;

a CDRH2 comprising an amino acid sequence of SEQ ID NO: 2;

a CDRH3 comprising an amino acid sequence of SEQ ID NO: 3;

a CDRL1 comprising an amino acid sequence of SEQ ID NO: 9;

a CDRL2 comprising an amino acid sequence of SEQ ID NO: 16; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 24; or

(f) a CDRH1 comprising an amino acid sequence of SEQ ID NO: 1;

a CDRH2 comprising an amino acid sequence of SEQ ID NO: 2;

a CDRH3 comprising an amino acid sequence of SEQ ID NO: 3;

a CDRL1 comprising an amino acid sequence of SEQ ID NO: 12;

a CDRL2 comprising an amino acid sequence of SEQ ID NO: 19; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 26.

23 . The method of claim 22 , wherein the PD-L1+ solid tumor is or is derived from breast cancer, ovarian cancer, head and neck cancer, bladder cancer, melanoma, mesothelioma, colorectal cancer, cholangiocarcinoma, pancreatic cancer, lung cancer, leiomyoma, leiomyosarcoma, kidney cancer, glioma, glioblastoma, endometrial cancer, esophageal cancer, biliary gastric cancer, prostate cancer, or combinations thereof.

24 . The bispecific antibody of claim 1 , wherein

the second light chain comprises:

a CDRL1 comprising the amino acid sequence of SEQ ID NO: 103;

a CDRL2 comprising the amino acid sequence of His-Asp-Thr; and

a CDRL3 comprising the amino acid sequence of SEQ ID NO: 97.

25 . The method of claim 13 , wherein

the second antigen binding region comprises:

(a) a CDRH1 comprising an amino acid sequence of SEQ ID NO: 1;

a CDRH2 comprising an amino acid sequence of SEQ ID NO: 2;

a CDRH3 comprising an amino acid sequence of SEQ ID NO: 3;

a CDRL1 comprising an amino acid sequence of SEQ ID NO: 103;

a CDRL2 comprising an amino acid sequence of His-Asp-Thr; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 97.

26 . The antibody of claim 15 , wherein

the light chain comprises:

a CDRL1 comprising the amino acid sequence of SEQ ID NO: 103;

a CDRL2 comprising the amino acid sequence of His-Asp-Thr; and

a CDRL3 comprising the amino acid sequence of SEQ ID NO: 97.

27 . The method of claim 22 , wherein

the antigen binding region comprises

a CDRH1 comprising an amino acid sequence of SEQ ID NO: 1;

a CDRH2 comprising an amino acid sequence of SEQ ID NO: 2;

a CDRH3 comprising an amino acid sequence of SEQ ID NO: 3;

a CDRL1 comprising an amino acid sequence of SEQ ID NO: 103;

a CDRL2 comprising an amino acid sequence of His-Asp-Thr; and

a CDRL3 comprising an amino acid sequence of SEQ ID NO: 97.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 15, 2025
From: CHAUCHET, XAVIER; MASTERNAK, KRZYSZTOF; SHANG, LIMIN; PENARRIETA, ELISE; FERLIN, WALTER
To: NOVIMMUNE SA
Reel/Frame 071715/0042 →
Continuity (3)
Provisional Application 63317892 · Mar 8, 2022
Provisional Application 63164237 · Mar 22, 2021
Related Publication 20220315654A1 · Oct 6, 2022
References Cited (143)
US 3773919A · Boswell et al. · 1973 [cited by applicant]
US 4485045A · Regen · 1984 [cited by applicant]
US 4522811A · Eppstein et al. · 1985 [cited by applicant]
US 4544545A · Ryan et al. · 1985 [cited by applicant]
US 4676980A · Segal et al. · 1987 [cited by applicant]
US 4816567A · Cabilly et al. · 1989 [cited by applicant]
US 5013556A · Woodle et al. · 1991 [cited by applicant]
US 5030719A · Umemoto et al. · 1991 [cited by applicant]
US 5225539A · Winter · 1993 [cited by applicant]
US 5545806A · Lonberg et al. · 1996 [cited by applicant]
US 5545807A · Surani et al. · 1996 [cited by applicant]
US 5569825A · Lonberg et al. · 1996 [cited by applicant]
US 5625126A · Lonberg et al. · 1997 [cited by applicant]
US 5633425A · Lonberg et al. · 1997 [cited by applicant]
US 5661016A · Lonberg et al. · 1997 [cited by applicant]
US 5916771A · Hori et al. · 1999 [cited by applicant]
US 5939598A · Kucherlapati et al. · 1999 [cited by applicant]
US 6075181A · Kucherlapati et al. · 2000 [cited by applicant]
US 6150584A · Kucherlapati et al. · 2000 [cited by applicant]
US 6528624B1 · Idusogie et al. · 2003 [cited by applicant]
US 9334331B2 · Igawa · 2016 [cited by examiner]
US 10421807B2 · Gonzales · 2019 [cited by examiner]
US 11260117B2 · Masternak · 2022 [cited by examiner]
US 12448444B2 · Chauchet · 2025 [cited by examiner]
US 20120184716A1 · Fischer et al. · 2012 [cited by applicant]
US 20220315655A1 · Chauchet · 2022 [cited by examiner]
US 20230295348A1 · Fischer · 2023 [cited by examiner]
US 20230355796A1 · Chao · 2023 [cited by examiner]
US 20230365682A1 · Chao · 2023 [cited by examiner]
US 20240002544A1 · Majocchi · 2024 [cited by examiner]
US 20240254234A1 · Majocchi · 2024 [cited by examiner]
US 20250171537A1 · Saro Suarez · 2025 [cited by examiner]
EP 1810979B1 · 2012 [cited by applicant]
EP 3722322A1 · 2020 [cited by applicant]
WO WO9100360A1 · 1991 [cited by applicant]
WO WO9220373A1 · 1992 [cited by applicant]
WO WO9308829A1 · 1993 [cited by applicant]
WO WO9402602A1 · 1994 [cited by applicant]
WO WO9411026A2 · 1994 [cited by applicant]
WO WO9522618A1 · 1995 [cited by applicant]
WO WO9627011A1 · 1996 [cited by applicant]
WO WO9633735A1 · 1996 [cited by applicant]
WO WO9634096A1 · 1996 [cited by applicant]
WO WO9953049A1 · 1999 [cited by applicant]
WO WO2010135558A1 · 2010 [cited by applicant]
WO WO2011084255A2 · 2011 [cited by applicant]
WO WO2012023053A2 · 2012 [cited by applicant]
WO WO2013088259A2 · 2013 [cited by applicant]
WO WO2014087248A2 · 2014 [cited by applicant]
WO WO2018215835A1 · 2018 [cited by applicant]
WO WO2019016411A1 · 2019 [cited by applicant]
WO WO2019234576A1 · 2019 [cited by applicant]
WO WO2022200387A1 · 2022 [cited by applicant]
WO WO2022200389A1 · 2022 [cited by applicant]
Dheilly et al. (Antibodies (Basel) Jan. 3, 2018;7(1):3). [cited by examiner]
Fischer et al (Nat Commun Feb. 12, 2015:6:6113). [cited by examiner]
Tang et al (Front. Drug Discov., 3: 1-16; May 8, 2023). [cited by examiner]
Vajda et al., Current Opinion in Structural Biology, 67 pp. 226-231 (2021). [cited by examiner]
Marks et al., J. Biol. Chem. 295(29) 9823-9837 (2020). [cited by examiner]
Akbar et al., Cell Reports 34, 108856, Mar. 16, 2021. [cited by examiner]
Lo et al., BMC Genomics vol. 22, Article No. 116 (2021). [cited by examiner]
Baldrick, P., “Pharmaceutical excipient development: the need for preclinical guidance,” Regulatory Toxicology and Pharmacology, Oct. 2000, 32(2), pp. 210-218. [cited by applicant]
Bobo et al. “Convection-enhanced delivery of macromolecules in the brain”, Proceedings of the National Academy of Sciences, Mar. 1994, 91(6), pp. 2076-2080. [cited by applicant]
Bowie et al., “A method to identify protein sequences that fold into a known three-dimensional structure”, Science. Jul. 12, 1991; 253(5016): 164-70. [cited by applicant]
Brodeur et al., “Mouse-Human Myeloma Partners for the Production of Heterohybridomas,” Monoclonal Antibody Production Techniques and Applications, Marcel Dekker, Inc., Mar. 1987, pp. 51-63. [cited by applicant]
Caron et al., “Engineered Humanized Dimeric Forms of IgG Are More Effective Antibodies” the Journal of Experimental Medicine, Oct. 1992, 176(4), pp. 1191-1195. [cited by applicant]
Chappell, S. et al., “A 9-nt segment of a cellular mRNA can function as an internal ribosome entry site (IRES) and when present in linked multiple copies greatly enhances IRES activity,” Proceedings of the National Acad… [cited by applicant]
Charman, W.N., “Lipids, lipophilic drugs, and oral delivery—some emerging concepts,” Journal of Pharmaceutical Sciences, Aug. 2000, 89(8), pp. 967-978. [cited by applicant]
Chothia, C. et al., “Canonical Structures for the Hypervariable Regions of Immunoglobins”, Journal of Molecular Biology, Aug. 1987, vol. 196, No. 4, pp. 901-917. [cited by applicant]
Cole, S. et al. “The EBV-Hybridoma Technique and Its Application to Human Lung Cancer,” Monoclonal Antibodies and Cancer Therapy 27, Jan. 1985, pp. 77-96. [cited by applicant]
Cote, R. et al., “Generation of human monoclonal antibodies reactive with cellular antigens,” Proceedings of the National Academy of Sciences, Apr. 1983, vol. 80, pp. 2026-2030. [cited by applicant]
Davidson, B.L. et al., “A model system for in vivo gene transfer into the central nervous system using an adenoviral vector,” Nature Genetics, Mar. 1993, vol. 3, pp. 219-223. [cited by applicant]
Davies et al., “Antibody-Antigen Complexes,” Annual Review Biochemistry, Jul. 1990, vol. 59, pp. 439-473. [cited by applicant]
Davis, J.H. et al., “SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies,” Protein … [cited by applicant]
Deuse, T., et al., “The SIRPα-CD47 immune checkpoint in NK cells,” Journal of Experimental Medicine, Mar. 2021, vol. 218, No. 3, 25 pages. [cited by applicant]
Dumet et al., “Insights into the LgG heavy chain engineering patent landscape as applied to LgG4 antibody development,” mAbs, Published: Sep. 2019, vol. 11, No. 8, pp. 1341-1350. [cited by applicant]
Eppstein et al., “Biological activity of liposome-encapsulated murine interferon γ is mediated by a cell membrane receptor,” Proceedings of the National Academy of Sciences, Jun. 1985, 82(11), pp. 3688-3692. [cited by applicant]
Fishwild et al., “High-avidity human IgGk monoclonal antibodies from a novel strain of minilocus transgenic mice,” Nature Biotechnology, Jul. 1996, 14(7), pp. 845-851. [cited by applicant]
Geller, A.I. et al., “An HSV-1 Vector Expressing Tyrosine Hydroxylase Causes Production and Release of L-DOPA from Cultured Rat Striatal Cells,” Journal of Neurochemistry, Feb. 1995, 64(2), pp. 487-496. [cited by applicant]
Geller, A.I. et al., “Infection of cultured central nervous system neurons with a defective herpes simplex virus 1 vector results in stable expression of [cited by applicant]
Geller, A.I. et al., “Long-term increases in neurotransmitter release from neuronal cells expressing a constitutively active adenylate cyclase from a herpes simplex virus type 1 vector,” Proceedings of the National Acad… [cited by applicant]
Goding, J.W. (Ed.) “Production of Monoclonal Antibodies”, in Monoclonal Antibodies: Principles and Practice, 2nd Edition, Academic Press, pp. 59-103 (1986). [cited by applicant]
Goulet R.G. and Atkins W.M., “Considerations for the Design of Antibody-Based Therapeutics,” Journal of Pharmaceutical Sciences, Jan. 2020, 109(1), pp. 74-103. [cited by applicant]
Gramer et al., “Production of stable bispecific IgG1 by controlled Fab-arm exchange: Scalability from bench to large-scale manufacturing by application of standard approaches,” mAbs, Nov. 2013, 5(6), pp. 962-973. [cited by applicant]
Gruber et al., “Efficient Tumor Cell Lysis Mediated by a Bispecific Single Chain Antibody Expressed in [cited by applicant]
Gunasekaran et al., “Enhancing antibody Fe heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG,” Journal of Biological Chemistry, Jun. 2010, 285(25), pp.… [cited by applicant]
Hellen, C.U. and Sarnow, P., “Internal ribosome entry sites in eukaryotic mRNA molecules,” Genes & Development, Jul. 2001, 15(13), pp. 1593-1612. [cited by applicant]
Holliger et al., “‘Diabodies’: Small bivalent and bispecific antibody fragments,” Proceedings of the National Academy of Sciences, Jul. 1993, 90(14), pp. 6444-6448. [cited by applicant]
Honegger et al., “Yet another numbering scheme for immunoglobulin variable domains: An automatic modeling and analysis tool,” Journal of Molecular Biology, Jun. 2001, 309(3), pp. 657-670. [cited by applicant]
Hoogenboom, H.R. and Winter, G., “By-passing Immunisation. Human Antibodies from Synthetic Repertoires of Germline VH Gene Segments Rearranged in Vitro,” Journal of Molecular Biology, Sep. 1992, 227(2), pp. 381-388. [cited by applicant]
Husain, B., et al., “Expanding the boundaries of biotherapeutics with bispecific antibodies,” Biodrugs, vol. 12, No. 5, Aug. 21, 2018, pp. 441-464, XP55655206. [cited by applicant]
Hwang et al., “Hepatic uptake and degradation of unilamellar sphingomyelin/cholesterol liposomes: A kinetic study,” Proceedings of the National Academy of Sciences, Jul. 1980, 77(7), pp. 4030-4034. [cited by applicant]
Jansen et al., “Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity,” Immunological Reviews, Feb. 1982, 62(1), pp. 185-216. [cited by applicant]
Jones et al., “Replacing the complementary-determining regions in a human antibody with those from a mouse,” Nature, vol. 321, May 1986, pp. 522-525. [cited by applicant]
Kaplitt, M. G. et al., “Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain,” Nature Genetics, Oct. 1994, 8(2), pp. 148-154. [cited by applicant]
Killen and Lindstrom, “Specific killing of lymphocytes that cause experimental autoimmune myasthenia gravis by ricin toxin-acetylcholine receptor conjugates,” The Journal of Immunology, Nov. 1984, 133(5), pp. 2549-1553. [cited by applicant]
Klein, C. et al. “Progress in overcoming the chain association issue in bispecific heterodimeric IgG antibodies,” InMAbsm, Nov. 2012, 4(6), pp. 653-663. [cited by applicant]
Kohler G. and Milstein C., “Continuous cultures of fused cells secreting antibody of predefined specificity,” Nature, Aug. 1975, 256(5517), pp. 495-497. [cited by applicant]
Kontermann, R. et al., “Complement recruitment using bispecific diabodies,” Nature Biotechnology, Jul. 1997, 15(7), pp. 629-631. [cited by applicant]
Kostelny et al., “Formation of a Bispecific Antibody by the Use of Leucine Zippers,” The Journal of Immunology, Mar. 1992, 148(5), pp. 1547-1553. [cited by applicant]
Kozbor et al., “A human hybrid myeloma for production of human monoclonal antibodies,” The Journal of Immunology, Dec. 1984, 133(6), pp. 3001-3005. [cited by applicant]
Kozbor et al., “The production of monoclonal antibodies from human lymphocytes,” Immunology Today, Mar. 1983, 4(3), pp. 72-79. [cited by applicant]
La Salle et al., “An Adenovirus Vector for Gene Transfer into Neurons and Glia in the Brain,” Science, Feb. 1993, 259(5097), pp. 988-990. [cited by applicant]
Lefranc, M-P., et al., “IMGT, the international ImMunoGeneTics database,” Nucleic Acids Research, Jan. 1999, 27(1), pp. 209-212. [cited by applicant]
Lefranc, M-P., “Immunoglobulins: 25 Years of Immunoinformatics and IMGT-Ontology,” Biomolecules, Dec. 2014, 4(4), pp. 1102-1139; doi: 10.3390/biom4041102. [cited by applicant]
Lim, F., et al., in DNA Cloning: Mammalian Systems, D. Glover, Ed. (Oxford Univ. Press, Oxford England, (1995), 23 pages. [cited by applicant]
Lonberg and Huszar, “Human Antibodies from Transgenic Mice,” International Reviews of Immunology, Jan. 1995, 13(1), pp. 65-93. [cited by applicant]
Lonberg et al., “Antigen-specific human antibodies from mice comprising four distinct genetic modifications,” Nature, Apr. 1994, 368(6474), pp. 856-859. [cited by applicant]
Lopez-Beltran, A., et al., “Immune checkpoint inhibitors for the treatment of bladder cancer,” Cancers, vol. 13, No. 1, 131, Jan. 3, 2021, XP055941080, DOI: 10.3390/cancers13010131, 16 pages. [cited by applicant]
Malmqvist, M., “Biosepcific interaction analysis using biosensor technology,” Nature, Jan. 1993, 361(6408), pp. 186-187. [cited by applicant]
Marasco et al., “Design, intracellular expression, and activity of a human anti-human immunodeficiency virus type 1 gpl20 single-chain antibody,” Proceedings of the National Academy of Sciences, Aug. 1993, 90(16), pp. 7… [cited by applicant]
Marks et al., “By-passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling,” Bio/Technology, Jul. 1992, 10(7), pp. 779-783. [cited by applicant]
Marks et al., “By-passing Immunization. Human Antibodies from V-gene Libraries Displayed on Phage,” Journal of Molecular Biology, Dec. 1991, 222(3), pp. 581-597. [cited by applicant]
Martin et al., “Irreversible Coupling of Immunoglobulin Fragments to Preformed Vesicles,” The Journal of Biological Chemistry, Jan. 1992, 257(1), pp. 286-288. [cited by applicant]
Milstein, C. & Cuello, A. C., “Hybrid hybridomas and their use in immunohistochemistry,” Nature, Oct. 1983, 305(5934), pp. 537-540. [cited by applicant]
Moore et al., “Application of dual affinity retargeting molecules to achieve optimal redirected T-cell killing of B-cell lymphoma,” Blood, The Journal of the American Society of Hematalogy, Apr. 2011, 117(17), pp. 4542-… [cited by applicant]
Morrison et al., “High-flow microinfusion: tissue penetration and pharmacodynamics,” American Journal of Physiology—Regulatroy, Intensive and Comparative Physiology, Jan. 1994, 266(1), pp. R292-R305. [cited by applicant]
Morrison, S. L., “Success in specification,” Nature, Apr. 1994, 368(6474), pp. 812-813. [cited by applicant]
Munson et al., “Ligand: A Versatile Computerized Approach for Characterization of Ligand-Binding Systems,” Analytical Biochemistry, Sep. 1980, 107(1), pp. 220-239. [cited by applicant]
Namisaki et al., “R409K Mutation prevents acid-induced aggregation of human LgG4,” Plos One, Mar. 17, 2020, 15(3), e0229027, 20 pages. [cited by applicant]
Neuberger, M., “Generating high-avidity human Mabs in mice,” Nature Biotechnology, Jul. 1996, 14(7), pp. 826. [cited by applicant]
Presta, L.G., “Antibody engineering,” Current Opinion in Structural Biology, Aug. 1992, 2(4), pp. 593-596. [cited by applicant]
Pörtner, L. et al., “T and NK cells of B cell NHL patients exert cytotoxicity against lymphoma cells following binding of bispecific tetravalent antibody CD19 x CD3 or CD19 x CD16,” Cancer Immunology, Immunotherapy, Oct… [cited by applicant]
Ramakrishnan, S. and Houston, L.L., “Comparison of the Selective Cytotoxic Effects of Immunotoxins Containing Ricin A Chain or Pokeweed Antiviral Protein and Anti-Thy 1.1 Monoclonal Antibodies,” Cancer Research, Jan. 19… [cited by applicant]
Ridgway et al., “‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization,” Protein Engineering, Design and Selection, Jul. 1996, 9(7), pp. 617-621. [cited by applicant]
Riechmann, L. et al. (Mar. 1988), “Reshaping human antibodies for therapy,” Nature, vol. 332, No. 6162, pp. 323-327. [cited by applicant]
Ruiz et al., “IMGT, the international ImMunoGeneTics database,” Nucleic Acids Research, Jan. 2000, 28(1), pp. 219-221. [cited by applicant]
Shopes, B., “A genetically engineered human IgG mutant with enhanced cytolytic activity,” The Journal of Immunology, May 1992, 148(9), pp. 2918-2922. [cited by applicant]
Stevenson et al., “A chimeric antibody with dual Fc regions (bisFabFc) prepared by manipulations at the IgG hinge,” Anti-Cancer Drug Design, Mar. 1989, 3(4), pp. 219-230. [cited by applicant]
Strohl, W.R., “Optimization of Fc-mediated effector functions of monoclonal antibodies,” Current Opinion in Biotechnology, Dec. 2009, 20(6), pp. 685-691. [cited by applicant]
Suresh et al., “Bispecific Monoclonal Antibodies from Hybrid Hybridomas,” Methods in Enzymology, January 198, vol. 121, pp. 210-228. [cited by applicant]
Thornton et al. “Prediction of progress at last”, Nature, Nov. 1991, 354(6349), pp. 105-106. [cited by applicant]
Traunecker et al., “Bispecific single chain molecules (Janusins) target cytotoxic lymphocytes on HIV infected cells,” The EMBO Journal, Dec. 1991, 10(12), pp. 3655-3659. [cited by applicant]
Tutt et al., “Trispecific F(ab′)3 Derivatives that Use Cooperative Signaling via the TCR/CD3 Complex and CD2 to Activate and Redirect Resting Cytotoxic T Cells,” The Journal of Immunology, Jul. 1991, 147(1), pp. 60-69. [cited by applicant]
Vaughan et al., “Human antibodies with sub-nanomolar affinities isolated from a large non-immunized phage display library,” Nature Biotechnology, Mar. 1996, 14(3), pp. 309-314. [cited by applicant]
Verhoeyen, M., et al., “Reshaping human antibodies: grafting an antilysozyme activity”, Science, Mar. 1988, 239(4847), pp. 1534-1536. [cited by applicant]
Vitetta et al., “Redesigning Nature's Poisons to Create Anti-Tumor Reagents,” Science, Nov. 1987, 238(4830), pp. 1098-1104. [cited by applicant]
Von Kreudenstein, T. et al., “Improving biophysical properties of a bispecific antibody scaffold to aid developability: quality by molecular design,” InMAbs, Sep. 2013, 5(5), pp. 646-654. [cited by applicant]
Wang, W., “Lyophilization and development of solid protein pharmaceuticals,” International Journal of Pharmaceutics, Aug. 2000, 203(1-2), pp. 1-60. [cited by applicant]
Wang, Y., et al., “Tumor-selective blockade of CD47 signaling with a CD47/PD-L1 bispecific antibody for enhanced anti-tumor activity and limited toxicity,” Cancer Immunology Immunotherapy, vol. 70, No. 2, Aug. 6, 2020, … [cited by applicant]
Wilkinson, D., “Ultimate Abs,” The Scientist 25, Apr. 17, 2000, vol. 14, No. 8, pp. 25-28. [cited by applicant]
Wolf, E. et al., “BiTEs: bispecific antibody constructs with unique anti-tumor activity,” Drug Discovery Today, Sep. 2005, 10(18), pp. 1237-1244. [cited by applicant]
Yang, et al., “Cellular and Humoral Immune Responses to Viral Antigens Create Barriers to Lung-Directed Gene Therapy with Recombinant Adenoviruses,” Journal of Virology, Apr. 1995, 69(4), pp. 2004-2015. [cited by applicant]